Clene Inc (CLNN) Stock Price, Quote & News

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; comp...

Industry: Packaged Foods

Sector: Consumer Defensive

Phone: 801 676 9695

Website: clene.com

Address:

6550 South Millrock Drive, Suite G50, Salt Lake City, United States

paule815 Feb. 24 at 3:27 PM

$CLNN check out our 6mo chart… Maybe it’s Mexico?

0 · Reply

Bbbb44444 Feb. 24 at 2:49 PM

$CLNN Anyone know what their cash runway is, assuming FDA accelerated approval?

2 · Reply

LXP Feb. 24 at 2:03 PM

$CLNN letter to shareholders tells me no news tomorrow. If they wait for fda minutes, which is likely, we won't hear anything until early Q2. So the waiting continues but the tone in that letter is so positive

2 · Reply

Woodman7 Feb. 24 at 1:52 PM

$CLNN - isn’t this kind of telling? Regarding the Phase 3 trial: “The trial design protocol has already been discussed with and reviewed by the FDA.”

2 · Reply

fibonacci1170 Feb. 24 at 1:28 PM

$CLNN I reckon CLNN will rise to more than $600MIL upon approval. Amlx drug was approved after it claimed 25% reduction in mortality, which it failed to replicate in the larger phase3. By contrast, cnmau8 reduces risk of mortality by 90% CONSISTENTLY across all it's trials, open label trials, and long-term follow-ups. In science, replication of results is sacrosanct. It will be tragic for ALS community if FDA doesn't even give CLNN a chance via accelerated approval.

0 · Reply

Mulhollandr Feb. 24 at 1:11 PM

$CLNN well, looks like Jinsy is speaking on our behalf again tomorrow which is a very good thing.

2 · Reply

Chris150 Feb. 24 at 1:02 PM

$CLNN Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts https://invest.clene.com/news-releases/news-release-details/clene-issues-stockholder-letter-highlighting-upcoming-cnm-au8r

2 · Reply

TheTradeXchange Feb. 24 at 1:01 PM

$CLNN - Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

0 · Reply

Woodman7 Feb. 24 at 12:43 PM

$CLNN - thinking of adding to my already-to-big position here today. The risk/reward seems significantly skewed to the upside. I mean, how much could it go down?? Vs - how much could it go up? Base case - the presentation tomorrow is kinda a nothing-burger and anyone with high expectations sells. Worse case - another delay. Best case - how high can your imagination go??

1 · Reply

AIBioScanner Feb. 24 at 10:08 AM

$CLNN AI-Based Findings on CLNN After running CLNN through AI-driven quantitative framework (MACD, RSI, ADX, ATR, Bollinger Bands, Fibonacci, OBV, VWAP), the stock is showing a constructive short-term setup. CLNN is stabilizing around $4.60, near the 78.6% Fibonacci retracement — a key decision level. Current signals: • Bullish MACD crossover • ADX above 30 (active trend strength) • RSI near 60 (room for upside) • Price holding above the 20-day mean 1-Month Outlook: Higher-probability scenario: ➡ Breakout attempt above $4.68 ➡ Target zone $5.10–$5.30 ➡ With volume support, extension toward $5.50 Key support to maintain bullish bias: $4.40 This is a transition phase — not yet a confirmed long-term uptrend. The coming weeks will determine whether this develops into accumulation or remains a technical rebound. Not financial advice. Data-driven technical analysis only.

1 · Reply

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

Feb 19, 2026, 8:30 AM EST - 5 days ago

Clene to Present at the Emerging Growth Conference

Jan 12, 2026, 8:30 AM EST - 6 weeks ago

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting

Jan 9, 2026, 8:30 AM EST - 6 weeks ago

Clene Announces Registered Direct Offering of Over $28 Million

Dec 3, 2025, 8:00 AM EST - 2 months ago

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

Dec 2, 2025, 5:39 PM EST - 2 months ago

Clene to Provide CNM-Au8® ALS Program Update

Nov 20, 2025, 8:00 AM EST - 3 months ago

Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference

Nov 13, 2025, 8:00 AM EST - 3 months ago

Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

Oct 15, 2025, 8:30 AM EDT - 4 months ago

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Sep 25, 2025, 8:00 AM EDT - 5 months ago

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Sep 4, 2025, 8:30 AM EDT - 6 months ago

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:38 AM EDT - 6 months ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Aug 5, 2025, 8:30 AM EDT - 7 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference

Jun 30, 2025, 8:00 AM EDT - 8 months ago

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 9, 2025, 9:00 AM EDT - 9 months ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

May 7, 2025, 8:00 AM EDT - 10 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Apr 1, 2025, 8:30 AM EDT - 11 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 6, 2025, 8:30 AM EST - 1 year ago

Clene to Present at the 37TH Annual Roth Conference

Feb 27, 2025, 9:15 AM EST - 1 year ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 25, 2025, 8:00 AM EST - 1 year ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Dec 10, 2024, 8:30 AM EST - 1 year ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Jul 11, 2024, 9:00 AM EDT - 1 year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Clene Announces 1-for-20 Reverse Stock Split

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 21, 2024, 7:09 AM EDT - 1 year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

May 28, 2024, 7:30 AM EDT - 1 year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 14, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at Upcoming May Conferences

May 8, 2024, 8:00 AM EDT - 1 year ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Apr 16, 2024, 4:01 PM EDT - 2 years ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Feb 29, 2024, 8:00 AM EST - 2 years ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Dec 21, 2023, 11:25 AM EST - 2 years ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 14, 2023, 8:36 AM EST - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Nov 7, 2023, 8:00 AM EST - 2 years ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Oct 5, 2023, 10:00 AM EDT - 2 years ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 25, 2023, 4:00 PM EDT - 2 years ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

paule815 Feb. 24 at 3:27 PM

$CLNN check out our 6mo chart… Maybe it’s Mexico?

0 · Reply

Bbbb44444 Feb. 24 at 2:49 PM

$CLNN Anyone know what their cash runway is, assuming FDA accelerated approval?

2 · Reply

LXP Feb. 24 at 2:03 PM

2 · Reply

Woodman7 Feb. 24 at 1:52 PM

$CLNN - isn’t this kind of telling? Regarding the Phase 3 trial: “The trial design protocol has already been discussed with and reviewed by the FDA.”

2 · Reply

fibonacci1170 Feb. 24 at 1:28 PM

0 · Reply

Mulhollandr Feb. 24 at 1:11 PM

$CLNN well, looks like Jinsy is speaking on our behalf again tomorrow which is a very good thing.

2 · Reply

Chris150 Feb. 24 at 1:02 PM

2 · Reply

TheTradeXchange Feb. 24 at 1:01 PM

$CLNN - Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

0 · Reply

Woodman7 Feb. 24 at 12:43 PM

1 · Reply

AIBioScanner Feb. 24 at 10:08 AM

1 · Reply

7m3835d3 Feb. 23 at 7:40 PM

$CLNN i know it’s meaningless and just follows general market trends, but not loving this price action right now. Was hoping for some excitement so close to a milestone. Anyways, we go up soon!

1 · Reply

Chris150 Feb. 23 at 1:34 PM

$CLNN Emerging Growth Conference released the time schedule of presentations and Clene has a 30-minute slot between 1.45 - 2.15 ET. A 30 minutes presentation is indicative of substantial news and updates from Rob imo, not the typical 10-15 minutes of prior EGC presentations. https://emerginggrowth.com/emerging-growth-conference-90/

1 · Reply

idyllic421 Feb. 22 at 4:08 PM

$CLNN Big Pharma Comparison Traditional vs. Mechanistic Large pharmaceutical ALS assets (like past Biogen/Ionis programs) often fail due to lack of clinical benefit, even after robust biology. Clene’s approach targets cellular energy, not specific protein pathology — this is innovative but more uncertain from a regulatory standpoint. Patent & Market CNM-Au8 could become the first approved metabolic/neuroprotective therapy if successful. Current drugs offer modest progression slowing but no broad neuroprotection.Approval in ALS before confirmatory Phase 3 is complicated, despite FDA engagement.Clene is well‑positioned as a high‑risk, high‑reward biotech story in a space with limited effective treatments. Approval odds before Phase 3 are modest but meaningful, especially compared to typical ALS pipelines. A successful accelerated approval would be a major breakthrough, but it’s far from certain.

1 · Reply

idyllic421 Feb. 22 at 4:07 PM

$CLNN Other smaller biotech ALS efforts (like mitochondrial modulators, immunotherapies) are in early development. None have yet demonstrated a clear survival benefit like CNM-Au8 is suggesting. Pipeline Context: Most approaches either fail or show small effects. CNM-Au8’s survival signals and multiple disease contexts (MS, PD) add a unique differentiation, giving investors multiple potential value drivers. CLNN holds a distinct mechanism and broader pipeline scope versus many competitors still pursuing traditional gene or immune targets.

0 · Reply

idyllic421 Feb. 22 at 4:06 PM

$CLNN Potential Accelerated Approval Path Clnn is pursuing an accelerated approval pathway which lets the FDA grant early approval based on a surrogate biomarker that’s "reasonably likely to predict clinical benefit." The company is basing this on: NfL reduction correlating with survival across independent datasets. Earlier survival signals in the HEALEY ALS Platform Trial extension. The FDA has engaged with Clene repeatedly and provided a roadmap for accelerated approval, but originally said more data was needed and requested deeper analyses. An in-person Type C meeting is scheduled, which is a key regulatory milestone in H1 2026. Approval Odds (Professional Estimation, Not Guarantee) Considering: Biomarker evidence is improving — + Survival signals are present — + FDA guidance exists — + But: No definitive Phase 3 clinical endpoint yet — − ALS is historically high‑failure — − A balanced risk assessment might place CNM-Au8’s accelerated approval odds at low‑to‑moderate (~15–30%)

0 · Reply

idyllic421 Feb. 22 at 4:00 PM

$CLNN Approved / Known Drugs Riluzole (oldest, generic) – small survival benefit (months), modest effect. Radicava – approved, modest benefit and mixed evidence on progression. Relyvrio was approved in 2022 but has been withdrawn, ongoing debate over effectiveness. Comparison to CNM-Au8🙂 CNM-Au8 shows biomarker reductions tied to survival and survival signals in extension data — something older drugs struggle to show consistently. New biomarkers (NfL, GFAP, IGFBP7) correlate with outcomes, which is a strong scientific signal that may support regulatory decisions. Big pharma has multiple ALS failures recently (e.g., discontinued programs after negative trials), highlighting how difficult it is to show meaningful clinical benefit in ALS. Investor Insight: If CNM-Au8 can turn biomarker correlations into actual clinical effects, it could be more compelling than the modest benefits of current drugs — but it's still unproven until confirmatory trials complete.

0 · Reply

Acx21 Feb. 21 at 8:27 PM

$CLNN ervything we have heard from and about CLNN and what we have discussed in here led to this date: 25.02.2026. on Wednesday, I assume the future of CLNN will change from uncertainty and doubts to a clear path to commerzialition and consequently to an huge increase in thr stock price. God damd, yes I'm invested and thus biased but all signs are overwhelmingly positiv. And so I am. Let's make some money boys

4 · Reply

Takeover24 Feb. 21 at 4:38 PM

$CLNN https://neals.org/educational-webinars/cnm-au8-in-als-nih-expanded-access-program-eap-clinical-biomarker-update/

0 · Reply

Mulhollandr Feb. 21 at 4:32 PM

$CLNN seems like there might be something to talk about on Wednesday? https://neals.org/educational-webinars/cnm-au8-in-als-nih-expanded-access-program-eap-clinical-biomarker-update/

2 · Reply

biotrade123 Feb. 21 at 4:13 PM

$CLNN many option grants filed yesterday albeit not huge, highest number is around 6000 with a strike price of $4.73

0 · Reply

fibonacci1170 Feb. 21 at 7:17 AM

$CLNN How will the FDA deny the IGFBP7 biomarker data? Although these findings are exploratory and hypothesis-generating and require prospective confirmation, there is no reason to deny the drug to patients while the confirmatory phase-3 is running in parallel. Most importantly, unlike other drugs like tofersen and NurOwn that worked only on subgroups, CNM-Au8 showed benefit to the entire cohort of trial patients. I want to see what argument the Adcom and FDA statisticians can have against CNM-Au8. CNM-Au8 verdict will show how corrupt and brain-dead the FDA is. FDA is on trial here, not CLNN.

0 · Reply

Mulhollandr Feb. 20 at 9:46 PM

$CLNN well folks…here we are. Does next week provide clarity or just continue the waiting game? Regardless, we are closer now than ever before. Though I’d love to see the price higher right now, I think good days are coming.

1 · Reply

Market Cap	50.29M
Revenue (ttm)	340,000.00
Net Income (ttm)	-39.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11,588.24%
Debt to Equity Ratio	-0.37

Volume	79,400
Avg Vol	93,810
Day's Range	N/A - N/A
Shares Out	10.85M
Stochastic %K	58%
Beta	0.81
Analysts	Strong Sell
Price Target	$31.86